A recent study published in PLOS One has found that successful hepatitis B vaccination may reduce the risk of diabetes by up to 33 per cent.
Researchers at the University of California Irvine (UCI) have developed a simple cost-effective urine test that detects and confirms hepatitis C virus infections.
Curing hepatitis C in people who inject drugs is more cost effective than waiting until advanced liver disease occurs, studies have shown.
The US Food and Drug Administration (FDA) has approved the use for ledipasvir/sofosbuvir (Harvoni) for people with hepatitis C genotypes 4, 5 and 6, as well as people with HIV.
People from three major cities across the world have shared their stories on how the new hepatitis C treatment have changed their lives.
A clinical trial has shown that a new drug combination taken over 12 weeks, can effectively treat hepatitis C genotypes 1, 2, 4, 5 and 6.
The first World Hepatitis Summit in Glasgow (2-4 September 2015) was filled with a sense of history as the goal of eliminating viral hepatitis seemed closer than ever before.
South Australia has the lowest rate in the country, for monitoring for people with chronic hepatitis B. Less than two per cent of affected South Australians receive the regular check-ups they need.
ASHM has issued a set of advice for doctors faced with patients asking about importing generic hepatitis C medicines.
Twenty-seven health organisations have published an open letter letter to the Health Minister, Hon. Sussan Ley MP, urging the inclusion of breakthrough hepatitis C cures on the Pharmaceutical Benefits Scheme.
The Glasgow Declaration on Viral Hepatitis - concluding the first World Hepatitis Summit - calls on governments to implement and fund comprehensive hepatitis programmes in line with World Health Assembly Resolution 67.6.
Gilead reports that a combination of sofosbuvir and experimental 'pan-genotypic' NS5A inhibitor velpatasvir (GS-5816) has proven effective regardless of HCV genotype in four late-stage studies.
